JPS61146269A - Injection type subcataneous syringe - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to a device that facilitates the transdermal administration of medicines, and particularly to a device that has a simple structure and that allows different injection drugs to be interchanged. Concerning the relocation of a flexible injection hypodermic syringe device.

(Prior Art) There is a strong demand for a method of transdermally administering medicine that is relatively painless. For example, people with diabetes may need to receive one or more doses of insulin each day to maintain proper blood sugar balance. Because there is an aversion to injections using hypodermic needles, it is important for patients to comply with doctors' instructions on administering medications.
Diabetes management using one injection has always been an obstacle.

In the 1960s, hypodermic syringes (HVPODE) appeared on the market.
A device called the rmic jet 1njector was introduced. The syringe dispenses measured doses of the drug in the form of fine, high-velocity jets without the use of a hypodermic needle and with sufficient force to penetrate skin tissue. . The proper use of a jet syringe has been found to be a relatively painless and therefore more accessible method of introducing injectable drugs into body tissue. When used to inject insulin, the injectable drug spreads through a larger volume of subcutaneous tissue compared to the diffusion that occurs when a ball of insulin is injected with a conventional hypodermic needle. There is a further advantage in that As such, the body is able to absorb and absorb insulin more rapidly, and tissue damage is significantly reduced. □U.S. Patent No. 3.33 [1,276, U.S. Pat. No. 3,521', 633 and U.S. Pat.
No. 8.651 discloses the structure and operating method of a typical well-known injection type hypodermic syringe. In each publication, the nozzle member is attached to the end of the syringe body,
(above) discloses a device in which the pull member has a relatively small diameter orifice formed in its throat, said orifice being in communication with a hole leading through the bidirectional pulp member to the injection chamber; do. A piston is arranged in the front distribution chamber, and the piston is ? When driven by the spring, the injection drug in the chamber is discharged through the hole and out of the orifice of the nozzle member. Each of these patent publications also discloses a pulping device in which an injectable drug is extracted from a supply vial by the pulping device and guided through a series of holes and a two-way pulp into the injection chamber of the syringe. I can do it. Therefore, as mentioned above, the pulp is ``filling''.
position and when said piston is withdrawn, the resulting vacuum causes injection drug to be drawn from said vial and flow through said series of holes and said pulp to fill said injection chamber. let at the same time?
The spring is compressed. The pulp is then rotated to form a direct passage from the injection chamber to the nozzle orifice. When the syringe bird is withdrawn, the power spring rapidly drives the piston or plunger forward, forcing the injection out of the vestibule and through the orifice.

PROBLEM SOLVED BY THE INVENTION In these known syringes, the first vial must be removed and separated due to residual amounts of injection drug remaining in the various passageways leading from the supply vial to the injection chamber. It is not possible in an flN vehicle to interchange different types of injections by switching to a second vial filled with injections. For example, a physician may administer Ultralente (Pli Li1ly Compa) as a once-daily basal dose.
You may wish to prescribe an insulin injection regimen, such as a long-acting insulin, such as TMJ (trademark), supplemented with regular fast-acting insulin at mealtimes. In this replacement of such insulin types, when a second type is withdrawn from its vial into said injection chamber, a first type is removed from each passageway and chamber of said syringe. is important. In the known type of syringe described above, after administering the first injection, 12 units remain in each hole and each passage connecting the supply vial and the injection chamber! It was quite possible that there was more insulin than that. This residual amount makes the use of known syringes virtually indispensable for prescribing when different types of insulin are to be administered.

C) Effect of the present invention) The present invention is an improvement on the well-known technology. In particular, use of the present invention reduces residual ignition of injectable drug remaining in the syringe after injection to a negligible amount. Furthermore, the use of the present invention greatly simplifies the mechanical construction of the syringe device. In other words, using the present invention it is possible to eliminate the rotatable pulp and its associated housing, thereby reducing the cost of the device.
reduce

Means for solving problem C) U.S. Patent No. 3.908.65 by Fudge
The well-known injection type hypodermic syringe device disclosed in Publication No. 1 includes an injection drug vial holding device attached to the side of the syringe device main body, and an injection drug vial holding device attached to the side of the syringe device main body, and an injection drug chamber provided in the syringe holder from the vial. The pulping device, which controls the inflow of drug and the subsequent outflow of the syringe from the pre-dispensing chamber through the aforesaid orifice in the syringe nozzle, has been improved to a new design by completely eliminating fire. Ta. This makes the device structure very ugly.

According to the present invention, a low cost and reusable end, 0
A supply device is provided that brings an injection drug supply vial into contact with an orifice formed through a syringe nozzle. When filling the hypodermic injection device with an injectable drug, the membrane f-7 meter device and its associated supply vial are connected to the nozzle member of the syringe. By doing so, the opening formed through the sealing membrane is opened and the injection drug is drawn into the injection chamber through the syringe orifice when the syringe barrel is pulled. can. When performing an injection, the membrane cap device and the supply vial attached thereto are removed from the nozzle of the syringe gun, thereby closing the opening in the membrane and preventing leakage from the supply vial. . The person giving the injection positions the nozzle at the location on the skin where the injection is to be made and presses the throat. The power spring forces the piston to slide rapidly into the chamber and the injection is ejected through the orifice.

The structure of the adductor device effectively prevents air from entering the chamber when filling the chamber with the injection drug. Furthermore, for dimensional reasons, there is virtually no injectable remaining in the syringe gun after an injection has been made. For this purpose, a second supply vial containing a different injection drug can be immediately attached to the syringe and the chamber of the syringe can be filled with the measured injection drug, leaving no residual injection drug as in the case of Shushu products. is not mixed with new filling.

Of course, the next time you intend to inject a mixture of two or more injectables as a single dose using the device of the present invention, you will need to use the first supply, which is equipped with its own ar7ter device. A vial is connected to the syringe gun and a first quantity of injection drug can be withdrawn into the injection chamber. Then a second one with its own Ardeter device and a different injection drug was installed.
a supply vial is connected to the nozzle of the syringe gun and is capable of withdrawing a predetermined amount of the second injection drug into the injection chamber; is mixed with said first amount and this mixture is later injected as a single dose.

A primary object of the present invention is to provide an improved syringe device.

Another object of the present invention is to provide a syringe device with a more hourly construction compared to circumferential technology.

Yet another object of the present invention is to provide a jetting hypodermic syringe device in which the chamber of the device is filled with the injection drug through the same orifice as the injection is later made.

Another object of the present invention is to provide a hypodermic injection device that allows easy replacement of various types of injection drugs.

Still another object of the present invention is to connect the nozzle of the syringe with the supply vial so that air does not enter into the injection chamber when the injection chamber is filled from the supply vial.
It is an object of the present invention to provide a jet hypodermic syringe device having a supply vial fitted with an f-7° ter device.

DESCRIPTION OF THE PREFERRED EMBODIMENTS These and other objects and advantages of the present invention will become apparent from the detailed description of the exemplary embodiments set forth below, when read in conjunction with the accompanying drawings.

Reference is first made to FIG. 1, which shows, in cross-section, the internal structure of an axer unit forming part of an apparatus according to the invention. The above-mentioned a) J"deter unit is designated as a whole by 10. As is clear from this drawing, the adapter unit 10 basically consists of three members: a base member 12, a diaphragm seal type disc member 14, and a connecting ring member 16. Base member 12 is preferably injection molded from a sterilizable, non-toxic plastic material such as polysulfone. Base member 12 has a generally flat surface with an annular recess 20 formed therein. 18. A needle member 22 is centrally located in the base member 12 and extends outwardly from the surface opposite the surface 18. A needle member 22 is centrally located in the base member 12 and extends outwardly from the surface opposite the surface 18. As shown, the needle member 22 is penetrated to form a first hole 24 and a second hole 2.
6 are provided in the longitudinal direction. The first aperture 24 extends from an opening adjacent the needle tip 28 to a proximal outlet 30 proximate the needle base. The second aperture 26 extends between a lateral aperture 32 in the side wall of the needle member and an exit aperture 34 located approximately centrally in the circularly shaped surface 18.

Reference numerals 36 and 38 indicate two of a plurality of collet fingers adapted to fit around the neck of a circumferential injection vial. An axially slidable ring 40 encloses the collet members of the adapter unit 10 and compresses fingers such as collet fingers 36 and 38 to firmly support the neck of the injection vial. used to.

Disk-shaped and expandable! Earphragm seal type isk member 14 is preferably formed from a natural stem and has an annular bead 42 that cooperates with an annular groove 20 in surface 18 of base member 12. Similarly, disk member 1
4 has on its opposite surface an annular bead 44 adapted to mate with a corresponding annular groove provided in the connecting ring member 16. When the connection 1 hook member 16 is then adhered to the base member 12, the YIM disc member 14 is firmly gripped with a liquid-tight seal formed therebetween.

A cylindrical recess or cavity 4 is provided in the center of the rubber disc member 14.
6 is formed. As shown, the second hole 26 in the needle member 22 communicates with the cavity 46. The diaphragm membrane 48 integrally formed with and centrally located on the disc member 14 has a flat outer surface;
The inner surface has a beveled surface extending from the sidewall of the cavity 46 toward the geometric center of the disk member 14.

When manufacturing the disk member 14, the disk member 14 is stretched with a suitable length, and in the stretched state, a hole of a predetermined size is punched in the center of the diaphragm membrane 4B. It will end with Gunchi.

When the stretching force is then released, the hole shrinks to approximately a "diameter hole" and! It is located approximately at the center of the diaphragm membrane 48.

Although it should not be interpreted as a limitation, the dimensions of the t-earphragm membrane of the disk member 14 are approximately 0.05 (11B
From the deaf (11,3B1 audience (approx. 0. [] (] 2 to 0
．． 0.015 inches) and the cavity 46
The intersection with the cylindrical side wall is approximately 0.152 mm to 1.0 mm.
It has been found that tapering the slope to a thickness in the range of 16 m+x (approximately 0.006 to 0.40 inches) is most suitable. However, different dimensions may be used for natural bims having different durometer values Y.

The connecting ring member 16 is generally cylindrical in shape and is preferably made of the same type of plastic used in forming the base member 12 and has a bore 11 sulfoy (no
lysulfone) is non-toxic and approved by the Food and Drug Administration (
It is a material approved by FrlA) and exhibits satisfactory properties. The inner diameter of the coupling member 16 is sized to fit around the nozzle member of a jet hypodermic syringe, and is further provided with two L-shaped slots as shown at 50 in diametrically opposed locations. It is being L-shaped slot 50.5 (1 is A) as explained later
j' In order to secure the detergent unit 10 and the vial attached thereto to the injection hypodermic syringe, a cylindrical recess extending radially from the side of the nozzle member of said syringe is adapted to mate with the vial. There is.

Referring to Figure 2, there is a
7' terminal unit 10 is fixed to the neck of a standard pharmaceutical vial, that is, a standard injection drug vial 52, with the collet fingers 36 and 38 firmly gripping the metal cap portion 54 of the injection drug vial 52. A cross-sectional view is shown. The needle member 22 of the a1''-fter unit 10 pierces the rubber plug 56 of the injection drug vial 52, and the liquid injection drug flows into the lateral opening 32 of the needle member 22, and the second The proximal outlet 30 of the first hole 24 is oriented to fill the generally cylindrical cavity 46 through the hole 26 of the injection vial 52.
The cap is located below the cap and is therefore exposed to the atmosphere. There, when the liquid injection is caused to flow from the vial 52 into the recess or cavity 46,
A certain volume of air enters the first hole 24'! - is allowed to enter through, resulting in the pressure within the vial 52 being balanced, in other words maintained at a pressure equal to atmospheric pressure.

! Since the 4th diaphragm membrane is in a relaxed and undisturbed state, the "0 diameter hole" passing through it is closed! Liquid injections do not flow out through the diaphragm membrane 48.

In FIG. 2, the printer unit 10 and its associated injection vial 52 are suspended above the nozzle of a hypodermic syringe, but are not yet mechanically connected thereto.

Only a portion of the injection hypodermic syringe is shown, which is designated as a whole at 58. Body portion 60 of syringe 58
contains a spring (not shown) arranged to drive a piston 62 placed within the cylinder r hole 64. A nozzle member 66 is screwed into the head of the syringe 5B. A thin hole 68 is bored in the nozzle member 66,
The slot 68 terminates in an even smaller orifice 70 drilled into a hemispherical projection 72 of the nozzle member 66.

In FIG. 3, the axer unit 10 is shown at its insertion point 7 relative to the nozzle member 66 of the hypodermic syringe 52.
4 and 74 (FIG. 2) are secured by fitting into L-shaped slots (FIG. 1) provided in the side wall of the connecting ring member 16 of the axer unit 10. The hemispherical protrusion 72 of the nozzle member 66 is! earphram,
The membrane 48 is deflected into the cavity 46 of the disc member 14, and this deflection! It will be seen that the iaphragm membrane 48 is stretched and thereby opens a zero diameter hole through the membrane at its center. This now opened egg-like hole is aligned with orifice 70, with piston 62 directing the cylinder rearwardly within hole 64 to direct nozzle member 6.
When moved against 6, Shirin! A vacuum is created in the hole 6A, which draws the injection drug from the vial 52 through the lateral outlet 32 and the second longitudinal hole 26. Because of the first hole 2410, the pressure equalization hole, air is replaced by the volume of injection solution withdrawn from the vial 52.

Once the pre-measured dose has been withdrawn into the chamber of the jet syringe 58, the axer unit 10 reloads the syringe 58.
8 from the nozzle member 66 and by doing so! Earphragm membrane 48 self-seals to prevent spillage or leakage from injection vial 52. Syringe 58 is now ready for injection.

In order to obtain the necessary accuracy of the dose drawn and injected by the jet injector, it is important that atmospheric pressure is maintained within the pharmaceutical container. Pressure compensation using the device according to the invention requires the techniques described below.

In FIG. 4, the vial 52 and the anchor unit 10 fixed thereto are connected to a jet syringe 58 in the manner previously described;
and vial 52 are located in substantially the same vertical plane, and the vial is below the syringe so that the injection drug does not cover needle member 22. When in this position, when connected! The pressure due to the initial deflection of the diaphragm membrane 48 will be compensated by the escape of air through the base outlet 30. The assembly is then inverted as shown in FIG. 5 so that the needle member 22 is submerged within the injection.

When the assembly is held in the position of FIG. 5 for a short period of time, e.g.
The water level will rise above the level of the injectable drug inside. The prescribed injection dose is then withdrawn from the vial 52 into the injection chamber. When the injection is withdrawn, air will be replaced by the volume of insulin withdrawn from vial b2. That is, air will be seen to be drawn in from the base outlet 30 and rise up through the first hole 24 and entrain the injection solution as a bubble.

While holding the assembly in the position shown in FIG. 5, the X-deter unit 10 is twisted and removed from its bayonet connection.

Upon removal, the injection will remain in the cavity 46 and air will be excluded from it.

Once removed, the vial and adapter unit assembly can be stored in any position without spillage or spillage.

c) Advantages of the Invention It will be appreciated that the present invention eliminates the need to permanently secure the injection vial and the injection syringe, as was the case in the prior art. It also eliminates the prior art pulping device that guides the injection drug from the vial to the injection chamber of the jet syringe. Further use of the invention
Accordingly, it is possible to adapt to the replacement of injection drug types in the daily prescription of multiple types or the mixing of different injection drug types in individual injections. For example, in the treatment of diabetes, medical research has shown that ``intensified conventional treatment,'' which includes multiple types of injections every day.
tional thsrapy (ICT))
found that it can lead to complications that develop in long-term illnesses, such as blindness, kidney failure, heart disease, and limb disability. Use of the present invention provides greater flexibility in the use of various types of insulin,
This is available so that sterile mixing can be performed in actual daily ICT therapy practice.

The present invention provides those in need with the information needed to comply with the provisions of patent law and to implement this newly developed idea and to fabricate and use the special components needed. This has been described above in considerable detail for purposes of. However, it goes without saying that the invention may be carried out with a device different from the embodiments without departing from the scope of the invention itself, and that various modifications may be made to the details of the device and its method of operation. .

[Brief explanation of the drawing]

FIG. 1 shows an example of an embodiment forming part of the invention.
2 shows a cross-sectional view of the y°ter unit, and FIG. 2 shows a state in which the y°ter unit of FIG. 1 is connected to the injection vial, but not yet connected to the nozzle member of the hypodermic injection , and Figure 6 is a cross-sectional view showing the above-mentioned
Fig. 4 is a cross-sectional view showing the part where the fter unit and the vial connected thereto are connected to the nozzle member of the 11 injection hypodermic syringe, and Fig. 4 shows the filling operation of the assembly shown in Fig. 6. FIG. 5 is an elevational side view showing the attitude of the assembly in the first stage, and FIG. 5 is an elevational side view showing the attitude of the assembly in the second stage of the filling operation. 10... Adapter unit 12... Base member 1
4... Disk member (extensible member) 22... Needle member (-11' rope device) 24... First hole (maintenance device) 26... Second hole 28... Needle member Tip (point) 37... Lateral opening (second port) 36.38...
・Collet finger member (collet member) A6...vacancy (
recess) A8...t Earphragm membrane (expandable membrane) 52... Vial 56... Rubber plug (cap part) 58.
・Injection hypodermic syringe

Claims (9)

[Claims] (1) a syringe body, a syringe nozzle attachable to one end of the syringe body and having an orifice extending therethrough; an injection chamber adapted to receive a metered amount of injection medication via a delivery device;
and an ejection device for forcibly ejecting the predetermined measured amount of the injection drug through the orifice provided in the syringe nozzle. (A) an adapter device attachable to the parenteral drug supply vial, the adapter device including (a) a base member; (b) a retractable membrane abutting and cooperating with the base member; a retractable member defining a generally closed recess, the retractable membrane having a zero diameter hole formed therethrough; (c) a retractable membrane arranged to seal the recess when in a closed condition; and (c) the injection drug supply vial configured to convey liquid injection from the injection drug supply vial to the recess. (B) coupling the adapter device to the syringe nozzle and opening the zero diameter hole into the syringe nozzle; a coupling device provided on the syringe nozzle for opening the retractable membrane from its relaxed state to its expanded state, the zero diameter hole being opened when it is opened; a coupling device substantially aligned with the orifice in the syringe nozzle and arranged to permit fluid flow from the recess through the orifice and into the syringe chamber. Characteristic injection type hypodermic syringe device. (2) The device according to claim 1, wherein the adapter device is configured to provide a large amount of fluid in the injection drug supply vial when the injection drug in liquid form is conveyed into the recess and further into the injection chamber. A jet hypodermic syringe device that includes a maintenance device to maintain atmospheric pressure. (3) The device according to claim 1, wherein the syringe nozzle has a protrusion surrounding the orifice, and the protrusion has a shape corresponding to the contour of the recess. Hypodermic syringe device. (4) The apparatus according to claim 1, wherein the adapter unit includes a collet member for inserting and gripping the neck of the injection drug supply vial. (5) In the device according to claim 2, the probe device includes a needle member having a pointed end that pierces the cap portion of the injection drug supply vial, and the needle member is provided on its side wall. longitudinal first and second holes formed in the needle member to communicate respectively with first and second ports, the first hole being in communication with the atmosphere; , and the second hole is in communication with the recess. (6) In the device according to the first aspect of the claim, the stretchable membrane has a substantially circular shape in a plan view thereof;
and having a thinner thickness proximate said zero diameter hole than at its outer periphery. 7. A hypodermic injection device according to claim 1, wherein the retractable membrane is centrally formed integrally with the retractable member. (8) A hypodermic injection device according to claim 7, wherein the stretchable membrane is formed of an elastomeric material. (9) The device of claim 8, wherein the elastomeric material is rubber.